Yea, agreed.

I'm more worried there's some plausible way (like the ginger discussed) to negate the GLP-1 agonist's function itself or its net effects.

They're not going to talk about it in open industry journals, but Big Tobacco actually did do this with engineered high nicotine tobacco used to adjust addictivity levels.

https://en.wikipedia.org/wiki/Y1_(tobacco)#Legal_controversy